Literature DB >> 18300299

Validation of a rapid equilibrium dialysis approach for the measurement of plasma protein binding.

Nigel J Waters1, Rachel Jones, Gareth Williams, Bindi Sohal.   

Abstract

Equilibrium dialysis (ED) is one of the most frequently used approaches to investigate drug binding, where the major drawbacks are the time to reach equilibrium (varying between 6 and 24 h), a long assay preparation time and complexity of automation. A rapid equilibrium dialysis (RED) device has recently become commercially available (Pierce Biotechnology, ThermoFisher Scientific, Waltham, MA) offering the potential for reduced preparation and equilibration times. The RED device comprises a Teflon base plate which holds up to 48 disposable dialysis cells. Each dialysis insert is made up of two side-by-side chambers separated by a vertical cylinder of dialysis membrane with a high membrane surface area-to-volume ratio. An independent validation of the RED approach for the measurement of human plasma protein binding (PPB) was carried out as a comparative analysis with standard ED evaluating equilibration time, assay reproducibility and accuracy and ease of use. Using a diverse set of 18 commercially available drugs spanning a range of physicochemical properties we have shown this to be a robust and accurate methodology, with a shorter preparation and dialysis time, capable of being automated as a high-throughput assay for the determination of PPB. (c) 2008 Wiley-Liss, Inc. and the American Pharmacists Association

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18300299     DOI: 10.1002/jps.21317

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  79 in total

1.  Phase I study of veliparib in combination with gemcitabine.

Authors:  Ronald Stoller; John C Schmitz; Fei Ding; Shannon Puhalla; Chandra P Belani; Leonard Appleman; Yan Lin; Yixing Jiang; Salah Almokadem; Daniel Petro; Julianne Holleran; Brian F Kiesel; R Ken Czambel; Benedito A Carneiro; Emmanuel Kontopodis; Pamela A Hershberger; Madani Rachid; Alice Chen; Edward Chu; Jan H Beumer
Journal:  Cancer Chemother Pharmacol       Date:  2017-08-02       Impact factor: 3.333

2.  Incorporating human dosimetry and exposure into high-throughput in vitro toxicity screening.

Authors:  Daniel M Rotroff; Barbara A Wetmore; David J Dix; Stephen S Ferguson; Harvey J Clewell; Keith A Houck; Edward L Lecluyse; Melvin E Andersen; Richard S Judson; Cornelia M Smith; Mark A Sochaski; Robert J Kavlock; Frank Boellmann; Matthew T Martin; David M Reif; John F Wambaugh; Russell S Thomas
Journal:  Toxicol Sci       Date:  2010-07-16       Impact factor: 4.849

3.  Initial observations regarding free cortisol quantification logistics among critically ill children.

Authors:  Jerry J Zimmerman; Ruth M Barker; Rhona Jack
Journal:  Intensive Care Med       Date:  2010-08-19       Impact factor: 17.440

4.  Simulating the influence of plasma protein on measured receptor affinity in biochemical assays reveals the utility of Schild analysis for estimating compound affinity for plasma proteins.

Authors:  D Blakeley; D A Sykes; P Ensor; E Bertran; P J Aston; S J Charlton
Journal:  Br J Pharmacol       Date:  2015-10-22       Impact factor: 8.739

5.  In vitro and in vivo activities of HPi1, a selective antimicrobial against Helicobacter pylori.

Authors:  Ekaterina Gavrish; Binu Shrestha; Chao Chen; Ida Lister; E Jeffrey North; Lei Yang; Richard E Lee; Angel Han; Bronwyn Williams; David Charnuska; Ken Coleman; Kim Lewis; Michael D LaFleur
Journal:  Antimicrob Agents Chemother       Date:  2014-03-31       Impact factor: 5.191

6.  Brain Distributional Kinetics of a Novel MDM2 Inhibitor SAR405838: Implications for Use in Brain Tumor Therapy.

Authors:  Minjee Kim; Janice K Laramy; Gautham Gampa; Karen E Parrish; Richard Brundage; Jann N Sarkaria; William F Elmquist
Journal:  Drug Metab Dispos       Date:  2019-10-16       Impact factor: 3.922

7.  An In Vitro Caseum Binding Assay that Predicts Drug Penetration in Tuberculosis Lesions.

Authors:  Jansy P Sarathy; Hsin-Pin Ho Liang; Danielle Weiner; Jacqueline Gonzales; Laura E Via; Véronique Dartois
Journal:  J Vis Exp       Date:  2017-05-08       Impact factor: 1.355

8.  In vitro and in vivo activities of 2-aminopyrazines and 2-aminopyridines in experimental models of human African trypanosomiasis.

Authors:  Suman K Vodnala; Thomas Lundbäck; Birger Sjöberg; Richard Svensson; Martin E Rottenberg; Lars G J Hammarström
Journal:  Antimicrob Agents Chemother       Date:  2012-12-17       Impact factor: 5.191

9.  Design, synthesis and anti-tuberculosis activity of 1-adamantyl-3-heteroaryl ureas with improved in vitro pharmacokinetic properties.

Authors:  E Jeffrey North; Michael S Scherman; David F Bruhn; Jerrod S Scarborough; Marcus M Maddox; Victoria Jones; Anna Grzegorzewicz; Lei Yang; Tamara Hess; Christophe Morisseau; Mary Jackson; Michael R McNeil; Richard E Lee
Journal:  Bioorg Med Chem       Date:  2013-02-26       Impact factor: 3.641

10.  Prediction of Drug Penetration in Tuberculosis Lesions.

Authors:  Jansy P Sarathy; Fabio Zuccotto; Ho Hsinpin; Lars Sandberg; Laura E Via; Gwendolyn A Marriner; Thierry Masquelin; Paul Wyatt; Peter Ray; Véronique Dartois
Journal:  ACS Infect Dis       Date:  2016-07-06       Impact factor: 5.084

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.